{
  "abstract": "Clinical benefit from first-line PD-1 inhibitor plus chemotherapy in advanced ESCC remains heterogeneous, and PD-L1 alone provides limited stratification. We evaluated plasma lncRNA RIME as a potential biomarker for stratifying first-line treatment outcomes in a multicenter cohort of patients with advanced ESCC. In the chemotherapy plus PD-1 inhibitor group, RIME-low was associated with higher ORR and better PFS/OS, whereas RIME-high was associated with poorer outcomes. Joint RIME/PD-L1 assessment further distinguished clinical benefit. Nested-model analyses showed that RIME provided non-redundant outcome information beyond PD-L1, and treatment-by-RIME interactions supported an exploratory predictive signal for ORR and PFS. Overall, plasma RIME was associated with outcome stratification and represents a potential predictive biomarker for immunochemotherapy benefit in ESCC.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": "Article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "name": "Jia Liu",
      "orcid": "0000-0001-5835-5435"
    },
    {
      "name": "Rui-Qi Ren"
    },
    {
      "name": "Ye He"
    },
    {
      "name": "Qi-Hua Zhang"
    },
    {
      "name": "Xiao-Min Zhang"
    },
    {
      "name": "Xiao-Jing Luo"
    },
    {
      "name": "Yu-Zhe Cao"
    },
    {
      "name": "Qi-Nian Wu"
    },
    {
      "name": "Hui-Yan Luo",
      "orcid": "0000-0001-6312-9299"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6ynj2gaqaaw6k.bib",
  "cited_by": 0,
  "doi": "10.1016/j.isci.2026.117995",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13720606/?tool=EBI",
  "id": "6ynj2gaqaaw6k",
  "issns": [
    "2589-0042"
  ],
  "landing_url": "https://www.cell.com/iscience/fulltext/S2589-0042(26)03378-X",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "http://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Article"
    ],
    [
      "heading",
      "Oncology"
    ],
    [
      "heading",
      "Therapeutics"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7223295555",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13720606/pdf/?tool=EBI",
  "pmcid": "PMC13720606",
  "pmid": "42964759",
  "published": "2026-10-23",
  "publisher": "Elsevier BV",
  "ris": "https://research.draconitic.com/paper/6ynj2gaqaaw6k.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:16Z",
      "native_id": "10.1016/j.isci.2026.117995",
      "source": "feed-cell",
      "url": "https://www.cell.com/iscience/fulltext/S2589-0042(26)03378-X"
    },
    {
      "first_seen": "2026-10-30T12:17:49Z",
      "native_id": "10.1016/j.isci.2026.117995",
      "source": "crossref",
      "url": "https://linkinghub.elsevier.com/retrieve/pii/S258900422603378X"
    },
    {
      "first_seen": "2026-10-31T12:21:37Z",
      "native_id": "PMC:PMC13720606",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13720606"
    },
    {
      "first_seen": "2026-11-03T12:21:27Z",
      "native_id": "PMC13720606",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.isci.2026.117995"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "heading:Oncology",
      "subfield": "oncology"
    }
  ],
  "title": "A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC",
  "title_text": "A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T12:21:27Z",
  "url": "https://research.draconitic.com/paper/6ynj2gaqaaw6k",
  "venue": "iScience",
  "versions": []
}